FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769468085> ?p ?o ?g. }

• W2769468085 endingPage "916" @default.
• W2769468085 startingPage "902" @default.
• W2769468085 abstract "Despite considerable advances in cardiovascular disease treatment, heart failure remains a public health challenge. In this context, gene therapy appears as an attractive approach, but clinical trials using single therapeutic molecules result in moderate benefit. With the objective of improving ischemic heart failure therapy, we designed a combined treatment, aimed to simultaneously stimulate angiogenesis, prevent cardiac remodeling, and restore contractile function. We have previously validated IRES-based vectors as powerful tools to co-express genes of interest. Mono- and multicistronic lentivectors expressing fibroblast growth factor 2 (angiogenesis), apelin (cardioprotection), and/or SERCA2a (contractile function) were produced and administrated by intramyocardial injection into a mouse model of myocardial infarction. Data reveal that combined treatment simultaneously improves vessel number, heart function parameters, and fibrosis prevention, due to FGF2, SERCA2a, and apelin, respectively. Furthermore, addition of SERCA2a in the combination decreases cardiomyocyte hypertrophy. Large-scale transcriptome analysis reveals that the triple treatment is the most efficient in restoring angiogenic balance as well as expression of genes involved in cardiac function and remodeling. Our study validates the concept of combined treatment of ischemic heart disease with apelin, FGF2, and SERCA2a and shows that such therapeutic benefit is mediated by a more effective recovery of gene network regulation. Despite considerable advances in cardiovascular disease treatment, heart failure remains a public health challenge. In this context, gene therapy appears as an attractive approach, but clinical trials using single therapeutic molecules result in moderate benefit. With the objective of improving ischemic heart failure therapy, we designed a combined treatment, aimed to simultaneously stimulate angiogenesis, prevent cardiac remodeling, and restore contractile function. We have previously validated IRES-based vectors as powerful tools to co-express genes of interest. Mono- and multicistronic lentivectors expressing fibroblast growth factor 2 (angiogenesis), apelin (cardioprotection), and/or SERCA2a (contractile function) were produced and administrated by intramyocardial injection into a mouse model of myocardial infarction. Data reveal that combined treatment simultaneously improves vessel number, heart function parameters, and fibrosis prevention, due to FGF2, SERCA2a, and apelin, respectively. Furthermore, addition of SERCA2a in the combination decreases cardiomyocyte hypertrophy. Large-scale transcriptome analysis reveals that the triple treatment is the most efficient in restoring angiogenic balance as well as expression of genes involved in cardiac function and remodeling. Our study validates the concept of combined treatment of ischemic heart disease with apelin, FGF2, and SERCA2a and shows that such therapeutic benefit is mediated by a more effective recovery of gene network regulation." @default.
• W2769468085 created "2017-12-04" @default.
• W2769468085 creator A5006676284 @default.
• W2769468085 creator A5016400122 @default.
• W2769468085 creator A5022775659 @default.
• W2769468085 creator A5032740800 @default.
• W2769468085 creator A5034994959 @default.
• W2769468085 creator A5046142639 @default.
• W2769468085 creator A5049679674 @default.
• W2769468085 creator A5052310747 @default.
• W2769468085 creator A5059643149 @default.
• W2769468085 creator A5059955650 @default.
• W2769468085 creator A5066107207 @default.
• W2769468085 creator A5069667976 @default.
• W2769468085 creator A5083419707 @default.
• W2769468085 creator A5088946409 @default.
• W2769468085 creator A5091866377 @default.
• W2769468085 date "2018-03-01" @default.
• W2769468085 modified "2023-10-16" @default.
• W2769468085 title "Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart" @default.
• W2769468085 cites W1832822495 @default.
• W2769468085 cites W1887024293 @default.
• W2769468085 cites W1968647871 @default.
• W2769468085 cites W1969996799 @default.
• W2769468085 cites W1970137743 @default.
• W2769468085 cites W1972221671 @default.
• W2769468085 cites W1973883521 @default.
• W2769468085 cites W1973977262 @default.
• W2769468085 cites W1981577767 @default.
• W2769468085 cites W1986763722 @default.
• W2769468085 cites W1994446230 @default.
• W2769468085 cites W1999835234 @default.
• W2769468085 cites W2003297748 @default.
• W2769468085 cites W2005979110 @default.
• W2769468085 cites W2015860087 @default.
• W2769468085 cites W2026363818 @default.
• W2769468085 cites W2028273079 @default.
• W2769468085 cites W2035668312 @default.
• W2769468085 cites W2038225463 @default.
• W2769468085 cites W2042151937 @default.
• W2769468085 cites W2051206599 @default.
• W2769468085 cites W2055547255 @default.
• W2769468085 cites W2058950912 @default.
• W2769468085 cites W2073535977 @default.
• W2769468085 cites W2078224183 @default.
• W2769468085 cites W2078863695 @default.
• W2769468085 cites W2085092982 @default.
• W2769468085 cites W2088016747 @default.
• W2769468085 cites W2106727226 @default.
• W2769468085 cites W2123018722 @default.
• W2769468085 cites W2123490348 @default.
• W2769468085 cites W2127087522 @default.
• W2769468085 cites W2128593976 @default.
• W2769468085 cites W2133703765 @default.
• W2769468085 cites W2139287283 @default.
• W2769468085 cites W2159467067 @default.
• W2769468085 cites W2169414490 @default.
• W2769468085 cites W2171214255 @default.
• W2769468085 cites W2183997007 @default.
• W2769468085 cites W2206401146 @default.
• W2769468085 cites W2220787769 @default.
• W2769468085 cites W2271175958 @default.
• W2769468085 cites W2292493149 @default.
• W2769468085 cites W2325436143 @default.
• W2769468085 cites W2465228853 @default.
• W2769468085 cites W2620919080 @default.
• W2769468085 cites W2625006025 @default.
• W2769468085 doi "https://doi.org/10.1016/j.ymthe.2017.11.007" @default.
• W2769468085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5910659" @default.
• W2769468085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29249393" @default.
• W2769468085 hasPublicationYear "2018" @default.
• W2769468085 type Work @default.
• W2769468085 sameAs 2769468085 @default.
• W2769468085 citedByCount "17" @default.
• W2769468085 countsByYear W27694680852018 @default.
• W2769468085 countsByYear W27694680852019 @default.
• W2769468085 countsByYear W27694680852020 @default.
• W2769468085 countsByYear W27694680852021 @default.
• W2769468085 countsByYear W27694680852022 @default.
• W2769468085 countsByYear W27694680852023 @default.
• W2769468085 crossrefType "journal-article" @default.
• W2769468085 hasAuthorship W2769468085A5006676284 @default.
• W2769468085 hasAuthorship W2769468085A5016400122 @default.
• W2769468085 hasAuthorship W2769468085A5022775659 @default.
• W2769468085 hasAuthorship W2769468085A5032740800 @default.
• W2769468085 hasAuthorship W2769468085A5034994959 @default.
• W2769468085 hasAuthorship W2769468085A5046142639 @default.
• W2769468085 hasAuthorship W2769468085A5049679674 @default.
• W2769468085 hasAuthorship W2769468085A5052310747 @default.
• W2769468085 hasAuthorship W2769468085A5059643149 @default.
• W2769468085 hasAuthorship W2769468085A5059955650 @default.
• W2769468085 hasAuthorship W2769468085A5066107207 @default.
• W2769468085 hasAuthorship W2769468085A5069667976 @default.
• W2769468085 hasAuthorship W2769468085A5083419707 @default.
• W2769468085 hasAuthorship W2769468085A5088946409 @default.
• W2769468085 hasAuthorship W2769468085A5091866377 @default.
• W2769468085 hasBestOaLocation W27694680851 @default.
• W2769468085 hasConcept C104317684 @default.

• next